New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy

2016 ◽  
Vol 29 ◽  
pp. 90-106 ◽  
Author(s):  
Alberto A. Gabizon ◽  
Yogita Patil ◽  
Ninh M. La-Beck
Keyword(s):  
Cancer Therapy ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin

Role of Pegylated Liposomal Doxorubicin (PLD) in Epithelial Ovarian Cancer

2004 ◽  
Vol 16 (sup4) ◽  
pp. 98-103 ◽  
Author(s):  
D. Lorusso ◽  
G. Ferrandina ◽  
R. Lo voi ◽  
A. Fagotti ◽  
G. Scambia
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin

Epithelial Ovarian Cancer: Role of Pegylated Liposomal Doxorubicin in Prolonging the Platinum-Free Interval and Cancer Antigen 125 Trends During Treatment

2009 ◽  
Vol 19 (3) ◽  
pp. 361-366 ◽  
Author(s):  
JS Tanguay ◽  
J Ansari ◽  
L Buckley ◽  
I Fernando
Keyword(s):  
Median Overall Survival ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Free Interval ◽  
Response To Chemotherapy ◽  
Duration Of Response ◽  
Radiological Response

Background:Epithelial ovarian cancer's response to platinum retreatment depends on the duration of response to first-line platinum therapy. Platinum-free interval predicts subsequent platinum sensitivity and is a prognostic factor. Little has been published on the effect of pegylated liposomal doxorubicin (PLD) in the prolongation of treatment-free interval.Methods:Patients treated with PLD were reviewed to assess response to platinum retreatment after PLD and to establish the use of cancer antigen 125 (Ca125) trends. All patients treated with PLD had progressed within 12 months of prior platinum therapy. Cancer antigen 125 fluctuations were categorized as the variances from the baseline (±10%, ±10%-25%, and >25%). The response to chemotherapy was defined as Ca125 reduction from the baseline of more than 50%, clinical, or radiological response.Results:Fifty-nine women were identified. The response rate (RR) to PLD was 28.9%, and the median overall survival from PLD initiation was 62 weeks. The number of women demonstrating more than 25% reduction in Ca125 from the baseline increased progressively with each cycle; at cycle 2, 11%; cycle 3, 18%; cycle 4, 22%; and cycle 5, 27% (trend significant between cycles 2 and 4, P = 0.004). Fifteen patients were re-treated with platinum after progression after PLD with 80% (12/15) of the patients responding. The RR to platinum retreatment after PLD compares favorably with the historical data on the response to second-line platinum retreatment.Conclusions:The sole use of early Ca125 trends in PLD treatment before cycle 4 may result in an erroneous discontinuation of PLD in potential responders. Retreatment with platinum after PLD may yield a good RR in selected patients even those with disease progression within 12 months after prior platinum treatment.

Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines

2008 ◽  
Vol 34 (5) ◽  
pp. 391-406 ◽  
Author(s):  
Shailendra Verma ◽  
Susan Dent ◽  
Benjamin J.W. Chow ◽  
Daniel Rayson ◽  
Tamar Safra
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Liposomal Doxorubicin ◽  
Metastatic Breast ◽  
Pegylated Liposomal Doxorubicin

scholarly journals Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer

2013 ◽  
Vol 2013 ◽  
pp. 1-12 ◽  
Author(s):  
Carmela Pisano ◽  
Sabrina Chiara Cecere ◽  
Marilena Di Napoli ◽  
Carla Cavaliere ◽  
Rosa Tambaro ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Recurrent Ovarian Cancer ◽  
Phase Iii ◽  
Free Survival ◽  
Platinum Sensitive ◽  
Phase Iii Trials ◽  
Platinum Refractory

Among the pharmaceutical options available for treatment of ovarian cancer, increasing attention has been progressively focused on pegylated liposomal doxorubicin (PLD), whose unique formulation prolongs the persistence of the drug in the circulation and potentiates intratumor accumulation. Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. In 1999 it was first approved for platinum-refractory ovarian cancer and then received full approval for platinum-sensitive recurrent disease in 2005. PLD remains an important therapeutic tool in the management of recurrent ovarian cancer in 2012. Recent interest in PLD/carboplatin combination therapy has been the object of phase III trials in platinum-sensitive and chemonaïve ovarian cancer patients reporting response rates, progressive-free survival, and overall survival similar to other platinum-based combinations, but with a more favorable toxicity profile and convenient dosing schedule. This paper summarizes data clarifying the role of pegylated liposomal doxorubicin (PLD) in ovarian cancer, as well as researches focusing on adding novel targeted drugs to this cytotoxic agent.

Sign in / Sign up

Export Citation Format

Share Document